Redhill Biopharma Ltd. - ADR
RDHL
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.9M
Close$
$0.85
44.3% upside
Current Fair Value
44.3% upsideUndervalued by 44.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.90 Million |
|---|---|
| Enterprise Value | $-999,572.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 4.97 |
| Outstanding Shares | 1,803,002 |
Return
| Return on Equity | -218.21% |
|---|---|
| Return on Assets | -36.74% |
| Return on Invested Capital | -133.64% |
Valuation & Multiples
| P/E Ratio | -0.3 |
|---|---|
| PEG | -0.89 |
| Price to Sales | 0.12 |
| Price to Book Ratio | 0.3 |
| Enterprise Value to Revenue | -0.1 |
| Enterprise Value to EBIT | 0.12 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -1.07 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 9, 2026
EPS Estimate
$-435.00
Average shareholder expectationRevenue Estimate
$22.70 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-352.86
Average shareholder expectationRevenue Estimate
$24.29 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Redhill Biopharma
CEO: Dror Ben-Asher